Get in touch
Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.
We are at the AACR Annual Meeting booth #2449. Stop by!
The NTRK & RET NGS Fusion Profile is an RNA-based next-generation sequencing panel that detects translocations and fusions of the genes NTRK1, NTRK2, NTRK3 and RET with known and novel fusion partners. Point mutations in select exons of these four genes are also detected. Examples of some of the published fusions detectable in this test include CD74-NTRK1, LMNA-NTRK1, MPRIP-NTRK1, TPM3-NTRK1, SQSTM1-NTRK1, PPL-NTRK1, AFAP1-NTRK2, PAN3-NTRK2, TRIM24-NTRK2, BTBD1-NTRK3, ETV6-NTRK3, CCD6-RET (aka RET-PTC1), KIF5B-RET, and NCOA4-RET (aka RET-PTC3). This test may be used to select patients for the following FDA-approved therapies: NTRK- ROZLYTREK® (entrectinib), VITRAKVI® (larotrectinib) RET- GAVRETO (pralsetinib), RETEVMO (selpercatinib) See also NTRK NGS Fusion Panel and Lung NGS Fusion Panel (Complete or Limited).
Level of Service
FFPE tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. NYS clients please provide date and time of Collection.
81194, 81479 (as of 01/01/2021); Prior to CPT Code was 81479
*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
Last Updated: January 22, 2025